Your browser doesn't support javascript.
loading
The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis.
Stavast, Christiaan J; van Zuijen, Iris; Karkoulia, Elena; Özçelik, Arman; van Hoven-Beijen, Antoinette; Leon, Leticia G; Voerman, Jane S A; Janssen, George M C; van Veelen, Peter A; Burocziova, Monika; Brouwer, Rutger W W; van IJcken, Wilfred F J; Maas, Alex; Bindels, Eric M; van der Velden, Vincent H J; Schliehe, Christopher; Katsikis, Peter D; Alberich-Jorda, Meritxell; Erkeland, Stefan J.
Affiliation
  • Stavast CJ; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
  • van Zuijen I; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
  • Karkoulia E; Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
  • Özçelik A; Childhood Leukemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
  • van Hoven-Beijen A; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
  • Leon LG; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
  • Voerman JSA; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
  • Janssen GMC; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
  • van Veelen PA; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
  • Burocziova M; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
  • Brouwer RWW; Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
  • van IJcken WFJ; Erasmus MC, University Medical Center Rotterdam, Center for Biomics, Rotterdam, the Netherlands.
  • Maas A; Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands.
  • Bindels EM; Erasmus MC, University Medical Center Rotterdam, Center for Biomics, Rotterdam, the Netherlands.
  • van der Velden VHJ; Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands.
  • Schliehe C; Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands.
  • Katsikis PD; Erasmus MC, University Medical Center Rotterdam, Department of Hematology, Rotterdam, the Netherlands.
  • Alberich-Jorda M; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
  • Erkeland SJ; Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
Leukemia ; 36(3): 687-700, 2022 03.
Article in En | MEDLINE | ID: mdl-34741119
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA Polymerase II / Leukemia, Myeloid, Acute / MicroRNAs Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2022 Type: Article Affiliation country: Netherlands
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA Polymerase II / Leukemia, Myeloid, Acute / MicroRNAs Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2022 Type: Article Affiliation country: Netherlands